Carolyn Discafani

4.1k total citations · 1 hit paper
30 papers, 3.0k citations indexed

About

Carolyn Discafani is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Carolyn Discafani has authored 30 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 17 papers in Oncology and 9 papers in Organic Chemistry. Recurrent topics in Carolyn Discafani's work include HER2/EGFR in Cancer Research (6 papers), Cancer-related Molecular Pathways (6 papers) and Quinazolinone synthesis and applications (5 papers). Carolyn Discafani is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Cancer-related Molecular Pathways (6 papers) and Quinazolinone synthesis and applications (5 papers). Carolyn Discafani collaborates with scholars based in United States and Canada. Carolyn Discafani's co-authors include Allan Wissner, Philip Frost, Bernard D. Johnson, Ramaswamy Nilakantan, Ru Shen, Hwei‐Ru Tsou, Marvin F. Reich, Sridhar K. Rabindran, M. Brawner Floyd and William Hallett and has published in prestigious journals such as Journal of the American Chemical Society, Nature Medicine and Cancer Research.

In The Last Decade

Carolyn Discafani

30 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

2004 503 citations Sridhar K. Rabindran, Carolyn Discafani et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carolyn Discafani United States	23	1.4k	1.4k	872	569	357	30	3.0k
Peter Traxler Switzerland	30	2.7k 1.9×	1.6k 1.1×	1.1k 1.3×	465 0.8×	273 0.8×	61	4.6k
Steven A. Middleton United States	30	1.8k 1.3×	1.2k 0.9×	798 0.9×	373 0.7×	308 0.9×	63	3.7k
Karen Lackey United States	21	1.3k 0.9×	1.3k 0.9×	883 1.0×	516 0.9×	448 1.3×	32	2.8k
Laurent Hennequin France	22	1.5k 1.1×	973 0.7×	773 0.9×	500 0.9×	149 0.4×	52	2.7k
Judy Lucas United States	34	2.2k 1.6×	1000 0.7×	1.1k 1.2×	261 0.5×	382 1.1×	69	4.1k
Alan J. Kraker United States	34	2.7k 1.9×	2.2k 1.6×	1.2k 1.4×	319 0.6×	257 0.7×	46	4.8k
Jeff B. Smaill New Zealand	30	1.9k 1.3×	1.0k 0.7×	1.0k 1.2×	542 1.0×	235 0.7×	95	3.4k
Wilbur R. Leopold United States	32	2.9k 2.1×	2.5k 1.8×	1.0k 1.2×	1.1k 1.9×	379 1.1×	65	5.4k
Giorgio Caravatti Switzerland	26	1.5k 1.1×	713 0.5×	660 0.8×	213 0.4×	149 0.4×	45	2.3k
Anne T. Truesdale United States	13	1.1k 0.8×	972 0.7×	404 0.5×	505 0.9×	291 0.8×	16	2.3k

Countries citing papers authored by Carolyn Discafani

Since Specialization

Citations

This map shows the geographic impact of Carolyn Discafani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carolyn Discafani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carolyn Discafani more than expected).

Fields of papers citing papers by Carolyn Discafani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carolyn Discafani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carolyn Discafani. The network helps show where Carolyn Discafani may publish in the future.

Co-authorship network of co-authors of Carolyn Discafani

This figure shows the co-authorship network connecting the top 25 collaborators of Carolyn Discafani. A scholar is included among the top collaborators of Carolyn Discafani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carolyn Discafani. Carolyn Discafani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Beyer, Carl F., Nan Zhang, Richard Hernandez, et al.. (2008). TTI-237: A Novel Microtubule-Active Compound with In vivo Antitumor Activity. Cancer Research. 68(7). 2292–2300. 72 indexed citations

Zhang, Nan, Semiramis Ayral‐Kaloustian, Thai Nguyen, et al.. (2008). Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents. Bioorganic & Medicinal Chemistry. 17(1). 111–118. 25 indexed citations

Wang, Yanong D., Biqi Wu, S.A. Johnson, et al.. (2008). Synthesis, SAR study and biological evaluation of novel pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as anti-proliferative agents. Bioorganic & Medicinal Chemistry. 17(5). 2091–2100. 34 indexed citations

Boghaert, Erwin R., Kiran Khandke, Latha Sridharan, et al.. (2006). Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. International Journal of Oncology. 28(3). 675–84. 35 indexed citations

Sampath, Deepak, Lee M. Greenberger, Carl F. Beyer, et al.. (2006). Preclinical Pharmacologic Evaluation of MST-997, an Orally Active Taxane with Superior In vitro and In vivo Efficacy in Paclitaxel- and Docetaxel-Resistant Tumor Models. Clinical Cancer Research. 12(11). 3459–3469. 18 indexed citations

Tsou, Hwei‐Ru, William Hallett, Marvin F. Reich, et al.. (2005). Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity. Journal of Medicinal Chemistry. 48(4). 1107–1131. 246 indexed citations

Jennings, Lee D., Scott L. Kincaid, Yanong D. Wang, et al.. (2005). Parallel synthesis and biological evaluation of 5,6,7,8-tetrahydrobenzothieno[2,3-d]pyrimidin-4(3H)-one cytotoxic agents selective for p21-deficient cells. Bioorganic & Medicinal Chemistry Letters. 15(21). 4731–4735. 70 indexed citations

Golas, Jennifer M., Judy Lucas, Jonathan Golas, et al.. (2005). SKI-606, a Src/Abl Inhibitor withIn vivoActivity in Colon Tumor Xenograft Models. Cancer Research. 65(12). 5358–5364. 115 indexed citations

Yamashita, Ayako, Joshua A. Kaplan, Frank Loganzo, et al.. (2004). Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment. Bioorganic & Medicinal Chemistry Letters. 14(21). 5317–5322. 16 indexed citations

10.

Smith, Daniel W., Arie Zask, Frank Loganzo, et al.. (2004). Tubulin inhibitors. Synthesis and biological activity of HTI-286 analogs with B-segment heterosubstituents. Bioorganic & Medicinal Chemistry Letters. 14(16). 4329–4332. 5 indexed citations

11.

Discafani, Carolyn, Carl F. Beyer, Tami Annable, et al.. (2004). 524 MST-997: a novel taxane with superior efficacy that overcomes paclitaxel and docetaxel resistance in vitro and in vivo. European Journal of Cancer Supplements. 2(8). 160–160. 1 indexed citations

12.

Berger, Dan, Minu Dutia, Dennis Powell, et al.. (2003). Synthesis and evaluation of 4-Anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade. Bioorganic & Medicinal Chemistry Letters. 13(18). 3031–3034. 25 indexed citations

13.

Wissner, Allan, Marvin F. Reich, M. Brawner Floyd, et al.. (2002). Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2). Journal of Medicinal Chemistry. 46(1). 49–63. 212 indexed citations

14.

Boschelli, Diane H., Fei Ye, Yanong D. Wang, et al.. (2001). Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity. Journal of Medicinal Chemistry. 44(23). 3965–3977. 179 indexed citations

15.

Yu, Ker, Lourdes Toral‐Barza, Carolyn Discafani, et al.. (2001). mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.. Endocrine Related Cancer. 8(3). 249–258. 354 indexed citations

16.

Torrance, C, Peta E. Jackson, Elizabeth A. Montgomery, et al.. (2000). Combinatorial chemoprevention of intestinal neoplasia. Nature Medicine. 6(9). 1024–1028. 396 indexed citations

17.

Discafani, Carolyn, Marion L. Carroll, M. Brawner Floyd, et al.. (1999). Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochemical Pharmacology. 57(8). 917–925. 84 indexed citations

18.

Discafani, Carolyn, E.L. Squires, & G. D. Niswender. (1995). Functional State of Primary and Secondary Corpora Lutea in Pregnant Mares. Biology of Reproduction. 52. 293–297. 1 indexed citations

19.

Discafani, Carolyn, et al.. (1991). A quantitative in vivo mouse model used to assay inhibitors of tumor-induced angiogenesis.. PubMed. 51(4). 1339–44. 22 indexed citations

20.

Roth, Joel A., et al.. (1988). Secretory Breast Carcinoma in a Man. The American Journal of Surgical Pathology. 12(2). 150–154. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact